Silver Book Fact

Direct thrombin inhibitor reduced relative risk of venous thromboembolism

An investigational direct thrombin inhibitor reduced relative risk of venous thromboembolism after total hip replacement surgery by 65.7%—compared to a currently available treatment.

Fuji, T et al. Efficacy and Safety of Edoxaban Verus Enoxaparin for the Prevention of Venous Thrombembolism Following Total Hip Arthroplasty: STARS J-V Trial. Orlando, Florida: American Society of Hematology,2010 Annual Meeting; December 4-7, 2010. http://ash.confex.com/ash/2010/webprogram/Paper29404.html

Reference

Title
Efficacy and Safety of Edoxaban Verus Enoxaparin for the Prevention of Venous Thrombembolism Following Total Hip Arthroplasty: STARS J-V Trial
Publisher
American Society of Hematology,2010 Annual Meeting
Publication Date
December 4-7, 2010
Authors
Fuji, T et al.
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Cost-effectiveness of TAVR in sSAS patients
    Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY…  
  • In 1996, fewer than 2 in 3 patients were receiving beta-blocker drugs to prevent a second heart attack. In 2006, more than 97% of heart attack patients received these treatments,…  
  • Using medical imaging to diagnose and treat stroke leads to better outcomes and shorter hospital stays, which yields a net economic benefit of about $8 billion over 10 years.  
  • AFib practice guidelines reduce direct health care costs
    The use of practice guidelines in atrial fibrillation (AF) patients significantly decreased hospitalization and resource utilization—with an average decrease in 30-day total direct health care costs of around $1,400 per patient.  
  • Heart Failure Disease Management (DM) Program Reduces Hospitalizations and Overall Costs